Thermo Fisher Scientific, a global leader in scientific solutions with over $40 billion in annual revenue, has introduced two next-gen sequencing options for preimplantation genetic testing-aneuploidy (PGT-A) crucial in IVF and ICSI research. The Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit, compatible with Ion Torrent Genexus Integrated Sequencer, offer complete workflows for aneuploidy analysis. Additionally, under the Applied Biosystems brand, Thermo Fisher provides genetic analyzers like the SeqStudio Flex Series, ensuring high-quality Sanger sequencing and fragment analysis. These instruments offer enhanced flexibility, connectivity, and ease of use across various applications including genome editing confirmation, SNP detection, and cell line authentication.
MGI Tech Co. Ltd. pioneers DNA sequencing innovation, offering cutting-edge solutions for precision medicine and research. With global operations since 2016, MGI delivers state-of-the-art instruments and reagents worldwide. MGI’s latest Standard MPS 2.0 update for DNBSEQ™ platforms elevates sequencing quality by boosting Q40 base percentage, crucial for precise genetic analysis. This advancement enables enhanced detection of low-abundance mutations in oncology, infectious diseases, and liquid biopsy biomarkers like ctDNA.
Roche, established in 1896 in Basel, Switzerland, has evolved into the world’s leading biotech firm and diagnostics pioneer. Roche acquired Foundation Medicine Inc. (FMI) entirely in 2018, FMI is dedicated to advancing cancer genomics through its range of comprehensive genomic profiling (CGP) tests. Focused on personalized healthcare, Roche collaborates with stakeholders to enhance diagnostics and pharmaceuticals through clinical data insights. Roche’s Sample Prep Solutions streamline sample conversion to sequencing-ready libraries, ensuring simplicity and efficacy across diverse applications.
Agilent Technologies leads in life sciences, diagnostics, and applied chemistry, supplying global labs with instruments, services, and expertise for precise results. Agilent’s next-gen sequencing solutions, including SureSelect and Avida, streamline genomic analysis. With Integrated automation, QC platforms, and analysis software optimizing every NGS stage for accuracy and efficiency, these technologies are empowering scientific breakthroughs.
Promega leads in innovative solutions and technical support for the life sciences sector, boasting a portfolio of over 4,000 products spanning cell biology, DNA/RNA/protein analysis, and drug development. Headquartered in Madison, WI, USA, with branches in 16 countries and over 50 global distributors, Promega’s Spectrum Compact CE System provides an integrated solution for Sanger sequencing and fragment analysis, compatible with various sequencing chemistries and STR kits. It supports diverse genomic applications, including NGS base call verification and gene sequencing.
PacBio revolutionizes genome, transcriptome, and epigenome studies with cutting-edge sequencing systems, driving breakthroughs in human health. With innovative DNA, RNA, and protein technologies, PacBio is empowering global scientists across diverse fields. Recent launches include high-throughput library preparation kits optimized for the Revio sequencing system, marking a significant advancement in the long-read sequencing market. These kits offer automated, scalable solutions with a 40% cost reduction and 60% workflow time decrease, benefiting microbial, metagenome, and low-pass whole genome sequencing projects of varying budget scales.
Oxford Nanopore Technologies leads the charge in revolutionizing DNA and RNA sequencing through innovative technology, offering real-time, user-friendly analysis with rich data. Oxford’s New generation of sequencing technology enables real-time analysis of fragments of any length, with scalable formats and easy automation, making high-output sequencing accessible. The PromethION 2 Integrated (P2i) expands their product range, featuring robust onboard computing for real-time basecalling and analysis, eliminating the need for external resources. This democratizes high-quality sequencing, catering to diverse multiomic studies, from large genome sequencing to metagenomics and cost-effective full-transcript-length sequencing, showcasing versatility and efficiency.
Element Biosciences, a San Diego-based startup established in 2017, specializes in genetic analysis tools for research and diagnostics. Element’s AVITI platform, featuring AVIDITY technology, aims to democratize high-quality sequencing, offering affordability and accessibility to labs worldwide. Recently introduced AVITI24, a multi-omics platform allows direct cell profiling. AVITI24 enables simultaneous investigation of DNA, RNA, proteins, phosphoproteins, and cell structure within single cells, enhancing cancer research by facilitating comprehensive molecular analysis of tumor cells, including rare and difficult-to-detect variants, thereby advancing understanding and treatment strategies.
